Aurora Cannabis Launches Physician Education Platform to Boost Medical Cannabis Prescribing

Aurora Cannabis Expands Physician Education Platform to Enhance Medical Cannabis Prescribing

Aurora Cannabis Inc., a prominent player in the global medical cannabis sector based in Edmonton, Alberta, announces the launch of the English-language version of its Physician Experience Platform (PEP) in collaboration with Copeia, a leading German healthcare technology firm. This innovative platform aims to serve as a peer-to-peer educational resource for physicians, showcasing over 130 anonymized case studies that emphasize the real-world applications of medical cannabis in patient care. Each case study within the PEP provides detailed insights into patient histories, symptoms treated, therapeutic outcomes, dosage, product information, and previous treatments, thereby offering a comprehensive guide for healthcare professionals navigating the complexities of prescribing medical cannabis.

The introduction of the English version of the PEP follows the successful release of its German counterpart in early 2024, marking a significant advancement in international physician education regarding medical cannabis. Dr. Stephanie Lunn, Aurora's Director of Medical & Patient Affairs, highlights the initiative's potential to improve access to clinical knowledge among healthcare providers, thereby enhancing the quality and frequency of medical cannabis prescriptions. This effort comes at a time when physicians frequently face challenges due to the limited integration of cannabis education within conventional medical curricula, making platforms like PEP vital for fostering understanding and acceptance of cannabis-based therapies.

Garvin Hirt, CEO of Copeia, underscores the importance of the PEP in addressing the knowledge gaps that hinder physicians from prescribing medical cannabis confidently. By providing a searchable and comprehensive database of peer-reviewed case reports, the platform enables clinicians to access pertinent data and learn from the experiences of their peers. This initiative not only aims to promote informed decision-making in medical practice but also strives to enhance patient care globally by encouraging healthcare professionals to integrate cannabis-based therapies into their treatment plans more effectively.

In addition to the launch of the English PEP, Aurora Cannabis is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. Chief Financial Officer Simona King will engage in one-on-one meetings with investors, presenting the company's strategic investments and plans for delivering long-term shareholder value in the evolving medical cannabis landscape.

Aurora Cannabis continues to solidify its position as a leader in both the medical and recreational cannabis markets, with a diverse portfolio that includes brands such as Drift, San Rafael '71, and MedReleaf. The company's commitment to science and innovation, coupled with its efforts to enhance physician education, reflects its dedication to advancing the medical cannabis sector and improving patient outcomes worldwide.